CA2222000C - Produits extracellulaires abondants et leurs procedes de production et d'utilisation - Google Patents

Produits extracellulaires abondants et leurs procedes de production et d'utilisation Download PDF

Info

Publication number
CA2222000C
CA2222000C CA2222000A CA2222000A CA2222000C CA 2222000 C CA2222000 C CA 2222000C CA 2222000 A CA2222000 A CA 2222000A CA 2222000 A CA2222000 A CA 2222000A CA 2222000 C CA2222000 C CA 2222000C
Authority
CA
Canada
Prior art keywords
protein
ala
gly
seq
immunized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2222000A
Other languages
English (en)
Other versions
CA2222000A1 (fr
Inventor
Marcus A. Horwitz
Gunter Harth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/447,398 external-priority patent/US6761894B1/en
Application filed by University of California filed Critical University of California
Publication of CA2222000A1 publication Critical patent/CA2222000A1/fr
Application granted granted Critical
Publication of CA2222000C publication Critical patent/CA2222000C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des vaccins à base d'une ou plusieurs combinaisons de produits extracellulaires abondants de pathogènes et des procédés pour leur utilisation et leur production. Les produits extracellulaires les plus abondants ou prédominants d'un pathogène cible sont sélectionnés, quelle que soit leur immunogénécité moléculaire absolue, et utilisés comme vaccins pour stimuler une réponse immunitaire protective chez les mammifères contre l'infection ultérieure par le pathogène cible. Les produits extracellulaires les plus abondants peuvent être caractérisés et distingués par leur acide aminé terminal N respectif, leur acide aminé ou leurs séquences d'ADN. Les vaccins peuvent comprendre différentes combinaisons de produits extracellulaires, des sous-unités de ces derniers, ou des acides nucléiques codants, et de ce fait, il est possible d'obtenir un grand nombre de compositions immunothérapeutiques efficaces selon l'invention. Outre d'autres agents infectieux, les vaccins ainsi produits peuvent être utilisés pour stimuler une réponse immunitaire efficace contre les pathogènes intracellulaires et, en particulier, le Mycobacterium tuberculosis.
CA2222000A 1995-05-23 1996-05-23 Produits extracellulaires abondants et leurs procedes de production et d'utilisation Expired - Lifetime CA2222000C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US08/447,398 1995-05-23
US08/447,398 US6761894B1 (en) 1993-11-23 1995-05-23 Abundant extracellular products and methods for their production and use
US54592695A 1995-10-20 1995-10-20
US08/545,926 1995-10-20
US55114995A 1995-10-31 1995-10-31
US08/551,149 1995-10-31
US56835795A 1995-12-06 1995-12-06
US08/568,357 1995-12-06
PCT/US1996/007781 WO1996037219A1 (fr) 1995-05-23 1996-05-23 Produits extracellulaires abondants et leurs procedes de production et d'utilisation

Publications (2)

Publication Number Publication Date
CA2222000A1 CA2222000A1 (fr) 1996-11-28
CA2222000C true CA2222000C (fr) 2012-03-20

Family

ID=27503944

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2222000A Expired - Lifetime CA2222000C (fr) 1995-05-23 1996-05-23 Produits extracellulaires abondants et leurs procedes de production et d'utilisation

Country Status (7)

Country Link
EP (1) EP0828510A1 (fr)
JP (1) JPH11506320A (fr)
AU (1) AU6024596A (fr)
BR (1) BR9608894A (fr)
CA (1) CA2222000C (fr)
NZ (1) NZ309945A (fr)
WO (1) WO1996037219A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
JP2001512435A (ja) * 1997-01-21 2001-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 豊富な細胞外産物ならびにそれらの産生および使用方法
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
EP0972045A1 (fr) * 1997-04-02 2000-01-19 Statens Seruminstitut FRAGMENTS D'ACIDE NUCLEIQUE ET FRAGMENTS POLYPEPTIDIQUES DERIVES DE $i(M. TUBERCULOSIS)
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
EP1003779A1 (fr) * 1997-07-07 2000-05-31 Abbott Laboratories Reactifs et methodes utiles pour detecter des pathologies mammaires
WO1999024577A1 (fr) * 1997-11-10 1999-05-20 Statens Serum Institut Fragments d'acides nucleiques et fragments polypeptidiques derives de m. tuberculosis
FR2796397B1 (fr) * 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
GB0003082D0 (en) * 2000-02-10 2000-03-29 Glaxo Group Ltd Vaccine
AU2001270031B2 (en) * 2000-06-22 2005-11-03 Wyeth Holdings Corporation QS-21 and IL-12 as an adjuvant combination
AU2001271963A1 (en) * 2000-07-10 2002-01-21 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
MX2007005256A (es) 2004-11-16 2008-03-11 Crucell Holland Bv Vacunas multivalentes que comprenden vectores virales recombinantes.
GB2433740A (en) 2005-12-23 2007-07-04 Rapid Biosensor Systems Ltd Detection of tuberculosis infection
EP2368568A1 (fr) 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions et procédés pour antigènes immunodominants
US9610337B2 (en) * 2011-12-22 2017-04-04 The University of Sydney Centenary Institute of Cancer Medicine and Cell Biology Prevention and treatment of mycobacterium infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108745B1 (en) * 1988-08-16 1998-06-30 Univ California Tuberculosis and legionellosis vaccines and methods for their production
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
AU1097795A (en) * 1993-11-23 1995-06-13 Regents Of The University Of California, The Abundant extracellular products and methods for their production and use
WO1996005223A1 (fr) * 1994-08-12 1996-02-22 The Regents Of The University Of California Produits extracellulaires abondants, procedes pour les produire et leur utilisation

Also Published As

Publication number Publication date
EP0828510A1 (fr) 1998-03-18
MX9709053A (es) 1998-10-31
NZ309945A (en) 2001-04-27
AU6024596A (en) 1996-12-11
WO1996037219A1 (fr) 1996-11-28
JPH11506320A (ja) 1999-06-08
BR9608894A (pt) 1999-12-07
CA2222000A1 (fr) 1996-11-28

Similar Documents

Publication Publication Date Title
US6761894B1 (en) Abundant extracellular products and methods for their production and use
CA2222000C (fr) Produits extracellulaires abondants et leurs procedes de production et d'utilisation
KR100433750B1 (ko) 마이코박테리움튜베르큘로시스항원을포함하는폴리펩타이드및이를포함하는약제학적조성물
WO1997009428A9 (fr) Composes et methodes d'immunotherapie et de diagnostic de la tuberculose
CA2285625A1 (fr) Fragments d'acide nucleique et fragments polypeptidiques derives de m. tuberculosis
EP1005365B1 (fr) Epitopes d'un antigene extracellulaire
US6599510B1 (en) Abundant extracellular products and methods for their production and use
US7300660B2 (en) Abundant extracellular products and methods for their production and use
US6818223B2 (en) Abundant extracellular products and methods for their production and use
US7002002B2 (en) Abundant extracellular products and methods for their production and use
US20060182754A1 (en) Abundant extracellular products and methods for their production and use
US6752993B1 (en) Abundant extracellular product vaccines and methods for their production and use
AU728433B2 (en) Abundant extracellular products and methods for their production and use
US20030152584A1 (en) Abundant extracellular products and methods for their production and use
US20020150592A1 (en) Abundant extracellular products and methods for their production and use
AU6555599A (en) Abundant extracellular products and methods for their production and use
WO1996005223A1 (fr) Produits extracellulaires abondants, procedes pour les produire et leur utilisation
AU6968100A (en) Abundant extracellular products and methods for their production and use
MXPA97009053A (en) Abundant extracelular products and methods for production and
MXPA97001103A (en) Abundant extracelular products and methods for their production and

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160524